Mersana Therapeutics implements restructuring plan, will reduce workforce by 55%

Mersana Therapeutics (MRSN) announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company’s cash runway and furthering the development of emiltatug ledadotin, the company’s B7-H4-directed Dolasynthen ADC. Mersana’s strategic restructuring and reprioritization plan will reduce the company’s workforce by approximately 55% across functions. The workforce reduction is expected to be substantially complete by the end of the third quarter of 2025. The company will also reduce its research activities and eliminate its internal pipeline development efforts. In the near term, Mersana will focus Emi-Le development efforts on breast cancer to enable the generation of additional safety, tolerability and clinical activity data. Mersana plans to continue supporting its Phase 1 dose escalation work for XMT-2056 and its ongoing collaborations. Collectively, these actions are expected to provide the company with sufficient cash resources to support its current operating plan commitments into mid-2026.